Novel cardiac-specific biomarkers and the cardiovascular continuum

Biomarker Insights

Volumn 7, Issue , 2012, Pages 45-57

  Vassiliadis, Efstathios ^a,b   Barascuk, Natasha ^a,b   Didangelos, Athanasios ^c   Karsdal, Morten A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker continuum; Biomarkers; Cardiac matrikine; Cardiovascular continuum; Cardiovascular disease; Diagnostic markers; ECMR; Extracellular matrix remodeling

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; COLLAGENASE 3; CREATINE KINASE; CREATINE KINASE MB; GELATINASE A; GELATINASE B; HEART ENZYME; ISOPROSTANE DERIVATIVE; LIPOPROTEIN A; MATRIKINES; MATRILYSIN; MYELOPEROXIDASE; MYOGLOBIN; N(G),N(G) DIMETHYLARGININE; NEUTROPHIL COLLAGENASE; OSTEOPONTIN; PEPTIDES AND PROTEINS; STROMELYSIN; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIAC EXTRACELLULAR MATRIX; CARDIOVASCULAR CONTINUUM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CARDITIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME BLOOD LEVEL; EXTRACELLULAR MATRIX; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE INJURY; HEART MUSCLE NECROSIS; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW;

EID: 84860810012     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMI.S9536     Document Type: Review

References (142)

1. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. Dec 19, 2006;114(25):2850-2870.
2. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation. Dec 19, 2006;114(25):2871-2891.
3. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl. Apr 2005;23(1):S9-S17.
4. Barrios V, Escobar C. Rosuvastatin and cardiovascular continuum when time is important. J Am Coll Cardiol. Apr 13, 2010;55(15):1645-1646.
5. Barrios V, Escobar C. Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. Expert Rev Cardiovasc Ther. Nov 2009; 7(11):1317-1327.
6. O'Rourke MF, Safar ME, Dzau V. The Cardiovascular Continuum extended: aging effects on the aorta and microvasculature. Vasc Med. Dec 2010;15(6):461-468.
7. Young GP, Gibler WB, Hedges JR, et al. Serial creatine kinase-MB results are a sensitive indicator of acute myocardial infarction in chest pain patients with nondiagnostic electrocardiograms: the second Emergency Medicine Cardiac Research Group Study. Acad Emerg Med. Sep 1997;4(9): 869-877.
8. Jurlander B, Clemmensen P, Wagner GS, Grande P. Very early diagnosis and risk stratifcation of patients admitted with suspected acute myocar-dial infarction by the combined evaluation of a single serum value of cardiac troponin-T, myoglobin, and creatine kinase MB(mass). Eur Heart J. Mar 2000;21(5):382-9.
9. Newby LK, Storrow AB, Gibler WB, et al. Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation. Apr 10, 2001;103(14):1832-7.
10. Hedges JR, Young GP, Henkel GF, Gibler WB, Green TR, Swanson JR. Early CK-MB elevations predict ischemic events in stable chest pain patients. Acad Emerg Med. Jan 1994;1(1):9-16.
11. de Winter RJ, Koster RW, Sturk A, Sanders GT. Value of myoglobin, tro-ponin T, and CK-MBmass in ruling out an acute myocardial infarction in the emergency room. Circulation. Dec 15, 1995;92(12):3401-7.
12. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefnition of myocardial infarction. J Am Coll Cardiol. Sep 2000;36(3):959-69.
13. Moe KT, Wong P. Current trends in diagnostic biomarkers of acute coronary syndrome. Ann Acad Med Singapore. Mar 2010;39(3):210-5.
14. Capellan O, Hollander JE, Pollack C Jr, et al. Prospective evaluation of emergency department patients with potential coronary syndromes using initial absolute CK-MB vs. CK-MB relative index. J Emerg Med. May 2003;24(4):361-367.
15. Jernberg T, Lindahl B, James S, Ronquist G, Wallentin L. Comparison between strategies using creatine kinase-MB(mass), myoglobin, and tro-ponin T in the early detection or exclusion of acute myocardial infarction in patients with chest pain and a nondiagnostic electrocardiogram. Am J Cardiol. Dec 15, 2000;86(12):1367-1371, A5.
16. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. Oct 2, 2002;40(7): 1366-1374.
17. de Lemos JA, Antman EM, Giugliano RP, et al. Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram. Am Heart J. Sep 2000;140(3):373-378.
18. Stork TV, Wu AH, Muller-Bardorff M, et al. Diagnostic and prognostic role of myoglobin in patients with suspected acute coronary syndrome. North-Wurttemberg Infarction Study (NOWIS) Group. Am J Cardiol. Dec 15, 2000;86(12):1371-1374, A5.
19. Polanczyk CA, Lee TH, Cook EF, Walls R, Wybenga D, Johnson PA. Value of additional two-hour myoglobin for the diagnosis of myocardial infarction in the emergency department. Am J Cardiol. Feb 15, 1999;83(4):525-529.
20. Seed M, Doherty E, Stubbs P. Lipoprotein (a): a prothrombotic risk factor for coronary artery disease. J Cardiovasc Risk. Jun 1995;2(3):206-215.
21. Morrisett JD. The role of lipoprotein[a] in atherosclerosis. Curr Atheroscler Rep. May 2000;2(3):243-250.
22. Stubbs P, Seed M, Lane D, Collinson P, Kendall F, Noble M. Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. Eur Heart J. Sep 1998;19(9):1355-1364.
23. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. Aug 1990;82(2):495-506.
24. Angelin B. Therapy for lowering lipoprotein (a) levels 34. Curr Opin Lipidol. Dec 1997;8(6):337-341.
25. Kambayashi Y, Nakao K, Kimura H, et al. Biological characterization of human brain natriuretic peptide (BNP) and rat BNP: species-specific actions of BNP. Biochem Biophys Res Commun. Dec 14, 1990;173(2):599-605.
26. Kambayashi Y, Nakao K, Mukoyama M, et al. Isolation and sequence determination of human brain natriuretic peptide in human atrium 37. FEBS Lett. Jan 1, 1990;259(2):341-345.
27. Sudoh T, Minamino N, Kangawa K, Matsuo H. Brain natriuretic peptide-32: N-terminal six amino acid extended form of brain natriuretic peptide identified in porcine brain. Biochem Biophys Res Commun. Sep 15, 1988;155(2):726-732.
28. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. Mar 3, 1988;332(6159):78-81.
29. Raizada A, Bhandari S, Khan MA, et al. Brain type natriuretic peptide (BNP)- a marker of new millennium in diagnosis of congestive heart failure. Indian Journal of Clinical Biochemistry. 2007;22:4-9. Ref Type: Generic.
30. Shapiro BP, Chen HH, Burnett JC Jr, Redfeld MM. Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure. Mayo Clin Proc. Apr 2003;78(4):481-486.
31. Lewandrowski K, Chen A, Januzzi J. Cardiac markers for myocar-dial infarction. A brief review. Am J Clin Pathol. Dec 2002;118 Suppl: S93-S99.
32. Fukuda N, Terui T, Ohtsuki I, Ishiwata S, Kurihara S. Titin and troponin: central players in the frank-starling mechanism of the heart. Curr Cardiol Rev. May 2009;5(2):119-124.
33. Wilkinson JM, Grand RJ. Comparison of amino acid sequence of troponin I from different striated muscles. Nature. Jan 5, 1978;271(5640):31-35.
34. Adamcova M, Sterba M, Simunek T, Potacova A, Popelova O, Gersl V. Myocardial regulatory proteins and heart failure. Eur J Heart Fail. Jun 2006;8(4):333-342.
35. Adams JE III, Bodor GS, vila-Roman VG, et al. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation. Jul 1993;88(1): 101-106.
36. Kim LJ, Martinez EA, Faraday N, et al. Cardiac troponin I predicts short-term mortality in vascular surgery patients. Circulation. Oct 29, 2002;106(18):2366-2371.
37. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. Aug 19, 2003;108(7):833-838.
38. Muehlschlegel JD, Perry TE, Liu K Y, et al. Troponin is superior to electrocardiogram and creatinine kinase MB for predicting clinically significant myocardial injury after coronary artery bypass grafting. Eur Heart J. Jul 2009;30(13):1574-1583.
39. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation. Nov 27, 2007;116(22):2634-2653.
40. Rosenberg M, Zugck C, Nelles M, et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail. May 2008; 1(1):43-49.
41. Francia P, Balla C, Ricotta A, et al. Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure. Int J Cardiol. Sep 20, 2010.
42. Georgiadou P, Iliodromitis EK, Kolokathis F, et al. Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study. Eur J Clin Invest. Apr 2010;40(4):288-293.
43. Schoensiegel F, Bekeredjian R, Schrewe A, et al. Atrial natriuretic peptide and osteopontin are useful markers of cardiac disorders in mice. Comp Med. Dec 2007;57(6):546-553.
44. Kossmehl P, Schonberger J, Shakibaei M, et al. Increase of fibronectin and osteopontin in porcine hearts following ischemia and reperfusion. J Mol Med (Berl). Aug 2005;83(8):626-637.
45. Murry CE, Giachelli CM, Schwartz SM, Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol. Dec 1994;145(6):1450-1462.
46. Rittling SR, Denhardt DT. Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol. Mar 1999;7(2):103-613.
47. Giachelli CM, Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. Dec 2000;19(7):615-622.
48. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal. Jun 2011;5(2):111-122.
49. Bornsen L, Khademi M, Olsson T, Sorensen PS, Sellebjerg F. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler. Jan 2011;17(1):32-42.
50. Sfridaki A, Miyakis S, Pappa C, et al. Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma. J Hematol Oncol. 2011;4:22.
51. Maier T, Laubender RP, Sturm RA, et al. Osteopontin expression in plasma of melanoma patients and in melanocytic tumours. J Eur Acad Dermatol Venereol. Aug 12, 2011.
52. Xu L, Ma X, Wang Y, et al. The Expression and Pathophysiological Role of Osteopontin in Graves' Disease. J Clin Endocrinol Metab. Sep 7, 2011.
53. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. Sep 7, 2010;103(6):861-869.
54. Lorenzen JM, Nickel N, Kramer R, et al. Osteopontin in patients with idiopathic pulmonary hypertension. Chest. May 2011;139(5):1010-1017.
55. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem. Nov 19, 2004;279(47):48487-48490.
56. Sepulveda JL, Mehta JL. C-reactive protein and cardiovascular disease: a critical appraisal. Curr Opin Cardiol. Sep 2005;20(5):407-416.
57. rroyo-Espliguero R, Avanzas P, Cosin-Sales J, Aldama G, Pizzi C, Kaski JC. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J. Mar 2004;25(5):401-408.
58. Hung MJ, Cherng WJ, Yang NI, Cheng CW, Li LF. Relation of high-sensitivity C-reactive protein level with coronary vasospastic angina pectoris in patients without hemodynamically significant coronary artery disease. Am J Cardiol. Dec 1, 2005;96(11):1484-1490.
59. Shah SJ, Marcus GM, Gerber IL, et al. High-sensitivity C-reactive protein and parameters of left ventricular dysfunction. J Card Fail. Feb 2006;12(1):61-65.
60. Tanaka H, Tsurumi Y, Kasanuki H. Prognostic value of C-reactive protein and troponin T level in patients with unstable angina pectoris. J Cardiol. Apr 2006;47(4):173-179.
61. Tsakiris AK, Marnelos PG, Nearchou NS, Papadakis JE, Karatzis EN, Skoufas PD. The influence of thrombolytic therapy on C-reactive protein in ST-segment elevation acute myocardial infarction. Hellenic J Cardiol. Jul 2006;47(4):218-222.
62. Blum A, Safori G, Hous N, Lupovitch S. The prognostic value of high-sensitive C-reactive protein and cardiac troponin T in young and middle-aged patients with chest pain without ECG changes. Eur J Intern Med. Aug 2003;14(5):310-314.
63. Pepys MB, Hirschfeld GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. Apr 27, 2006; 440(7088):1217-1221.
64. Kraus VB, Jordan JM. Serum C-Reactive Protein (CRP), Target for Therapy or Trouble? Biomark Insights. 2007;1:77-80.
65. Dietrich M, Jialal I. The effect of weight loss on a stable biomarker of inflammation, C-reactive protein. Nutr Rev. Jan 2005;63(1):22-28.
66. Deitmar S, Anthoni C, Palmes D, Haier J, Senninger N, Bruwer M. Are leukocytes and CRP early indicators for anastomotic leakage after esophageal resection? Zentralbl Chir. Feb 2009;134(1):83-89.
67. Lee SS, Singh S, Link K, Petri M. High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum. Aug 2008;38(1):41-54.
68. Davis G, Baboolal N, Nayak S, McRae A. Sialic acid, homocysteine and CRP: potential markers for dementia. Neurosci Lett. Nov 20, 2009;465(3): 282-284.
69. Boger RH. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med. Jul 2005; 10 Suppl 1:S19-S25.
70. Boger RH. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med. Nov 2003;41(11):1467-1472.
71. Tousoulis D, Siasos G, Oikonomou E, et al. Asymmetric dimethylarginine (ADMA): is really a biomarker for cardiovascular prognosis? Int J Cardiol. Dec 1, 2011;153(2):123-125.
72. Wolf C, Lorenzen JM, Stein S, et al. Urinary asymmetric dimethylarginine (ADMA) is a predictor of mortality risk in patients with coronary artery disease. Int J Cardiol. Dec 13, 2010.
73. Tripepi G, Mattace RF, Sijbrands E, et al. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin J Am Soc Nephrol. Jul 2011;6(7):1714-1721.
74. Sinning C, Schnabel R, Peacock WF, Blankenberg S. Up-and-coming markers: myeloperoxidase, a novel biomarker test for heart failure and acute coronary syndrome application? Congest Heart Fail. Jul 2008; 14(4 Suppl 1):46-48.
75. Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin Chem. Aug 2009;55(8):1462-1470.
76. Loria V, Dato I, Graziani F, Biasucci LM. Myeloperoxidase: a new bio-marker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm. 2008:135625.
77. Wu AH. Novel biomarkers of cardiovascular disease: myeloperoxidase for acute and/or chronic heart failure? Clin Chem. Jan 2009;55(1):12-14.
78. Milne GL, Musiek ES, Morrow JD. F2-isoprostanes as markers of oxi-dative stress in vivo: an overview. Biomarkers. Nov 2005;10 Suppl 1: S10-S23.
79. Nourooz-Zadeh J. Key issues in F2-isoprostane analysis. Biochem Soc Trans. Oct 2008;36(Pt 5):1060-1065.
80. LeLeiko RM, Vaccari CS, Sola S, et al. Usefulness of elevations in serum choline and free F2-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome. Am J Cardiol. Sep 1, 2009;104(5):638-643.
81. Wiswedel I, Hirsch D, Carluccio F, Hampl H, Siems W. F2-isoprostanes as biomarkers of lipid peroxidation in patients with chronic renal failure. Biofactors. 2005;24(1-4):201-208.
82. Young IS. Oxidative stress and vascular disease: insights from isoprostane measurement. Clin Chem. Jan 2005;51(1):14-15.
83. Pelouch V, Dixon IM, Golfman L, Beamish RE, Dhalla NS. Role of extracellular matrix proteins in heart function. Mol Cell Biochem. Dec 22, 1993;129(2):101-120.
84. Brown L. Cardiac extracellular matrix: a dynamic entity. Am J Physiol Heart Circ Physiol. Sep 2005;289(3):H973-H974.
85. Burgess ML, McCrea JC, Hedrick HL. Age-associated changes in cardiac matrix and integrins. Mech Ageing Dev. Oct 2001;122(15):1739-1756.
86. Jourdan-Lesaux C, Zhang J, Lindsey ML. Extracellular matrix roles during cardiac repair. Life Sci. Sep 25, 2010;87(13-14):391-400.
87. Wesley RB, Meng X, Godin D, Galis ZS. Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler Thromb Vasc Biol. Mar 1998;18(3): 432-440.
88. Levick SP, Melendez GC, Plante E, McLarty JL, Brower GL, Janicki JS. Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res. Jan 1, 2011;89(1):12-19.
89. Bishop JE, Laurent GJ. Collagen turnover and its regulation in the normal and hypertrophying heart. Eur Heart J. May 1995;16 Suppl C:38-44.
90. Bishop JE, Rhodes S, Laurent GJ, Low RB, Stirewalt WS. The regulation of collagen deposition in the hypertrophying heart. Ann N Y Acad Sci. Mar 27, 1995;752:236-239.
91. de JS, van Veen TA, de Bakker JM, Vos MA, van Rijen HV. Biomarkers of myocardial fibrosis. J Cardiovasc Pharmacol. May 2011;57(5):522-535.
92. Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol. Mar 2010;48(3):504-511.
93. Espira L, Czubryt MP. Emerging concepts in cardiac matrix biology. Can J Physiol Pharmacol. Dec 2009;87(12):996-1008.
94. Piper C, Schultheiss HP, Akdemir D, Rudolf J, Horstkotte D, Pauschinger M. Remodeling of the cardiac extracellular matrix differs between volume-and pressure-overloaded ventricles and is specifc for each heart valve lesion. J Heart Valve Dis. Sep 2003;12(5):592-600.
95. Zannad F, Pitt B. Biomarkers of extracellular matrix turnover. Heart Fail Clin. Oct 2009;5(4):589-599.
96. Iraqi W, Rossignol P, Angioi M, et al. Extracellular cardiac matrix bio-markers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation. May 12, 2009;119(18):2471-2479.
97. Spinale FG. Myocardial matrix remodeling and the matrix metal-loproteinases: influence on cardiac form and function. Physiol Rev. Oct 2007;87(4):1285-1342.
98. Vassiliadis E, Veidal SS, Simonsen H, et al. Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosis. Biomarkers. Aug 2011;16(5):426-433.
99. Lopez B, Gonzalez A, Diez J. Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. Curr Opin Nephrol Hypertens. Mar 2004;13(2):197-204.
100. Hutchinson KR, Stewart JA Jr, Lucchesi PA. Extracellular matrix remodeling during the progression of volume overload-induced heart failure. J Mol Cell Cardiol. Mar 2010;48(3):564-569.
101. Baghelai K, Marktanner R, Dattilo JB, et al. Decreased expression of tissue inhibitor of metalloproteinase 1 in stunned myocardium. J Surg Res. Jun 1998;77(1):35-39.
102. Kandasamy AD, Chow AK, Ali MA, Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res. Feb 1, 2010;85(3):413-423.
103. Marchant D, McManus BM. Matrix metalloproteinases in the pathogenesis of viral heart disease. Trends Cardiovasc Med. Jan 2009;19(1):21-6.
104. Loftus IM, Naylor AR, Bell PR, Thompson MM. Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg. Jun 2002;89(6): 680-694.
105. Sundstrom J, Evans JC, Benjamin EJ, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocar-diographic left ventricular measures: the Framingham Heart Study. Circulation. Jun 15, 2004;109(23):2850-2856.
106. Didangelos A, Yin X, Mandal K, et al. Extracellular matrix composition and remodeling in human abdominal aortic aneurysms: a proteomics approach. Mol Cell Proteomics. Aug 2011;10(8):M111.
107. Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M, Mayr M. Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics. Sep 2010;9(9):2048-2062.
108. Didangelos A, Simper D, Monaco C, Mayr M. Proteomics of acute coronary syndromes. Curr Atheroscler Rep. May 2009;11(3):188-195.
109. Lombardi F, Belletti S, Battezzati PM, Pacciolla R, Biondi ML. MMP-1 and MMP-3 polymorphism and arrhythmia recurrence after electrical car-dioversion in patients with persistent atrial fibrillation. J Cardiovasc Med (Hagerstown). Jan 2011;12(1):37-42.
110. Lombard C, Saulnier J, Wallach J. Assays of matrix metalloproteinases (MMPs) activities: a review. Biochimie. Mar 2005;87(3-4):265-272.
111. Naito Y, Tsujino T, Lee-Kawabata M, et al. Matrix metalloproteinase-1 and -2 levels are differently regulated in acute exacerbation of heart failure in patients with and without left ventricular systolic dysfunction. Heart Vessels. May 2009;24(3):181-186.
112. Ramos-Fernandez M, Bellolio MF, Stead LG. Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis. Jan 2011;20(1):47-54.
113. Veidal SS, Karsdal MA, Vassiliadis E, et al. MMP Mediated Degradation of Type VI Collagen Is Highly Associated with Liver Fibrosis-Identification and Validation of a Novel Biochemical Marker Assay. PLoS One. 2011;6(9):e24753.
114. Vassiliadis E, Larsen D V, Clausen RE, et al. Measurement of CO3-610, a Potential Liver Biomarker Derived from Matrix Metalloproteinase-9 Degradation of Collagen Type III, in a Rat Model of Reversible Carbon-Tetrachloride-Induced Fibrosis. Biomark Insights. 2011;6:49-58.
115. Vassiliadis E, Veidal SS, Barascuk N, et al. Measurement of matrix metalloproteinase 9-mediated collagen type III degradation fragment as a marker of skin fibrosis. BMC Dermatol. 2011;11:6.
116. Leeming D, He Y, Veidal S, et al. A novel marker for assessment of liver matrix remodeling: An enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers. Oct 11, 2011.
117. Veidal SS, Karsdal MA, Nawrocki A, et al. Assessment of proteolytic degradation of the basement membrane: A fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair. Oct 5, 2011;4(1):22.
118. Karsdal MA, Delvin E, Christiansen C. Protein fingerprints-Relying on and understanding the information of serological protein measurements. Clin Biochem. Nov 2011;44(16):1278-1279.
119. Veidal SS, Vassiliadis E, Barascuk N, et al. Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int. Oct 2010;30(9):1293-1304.
120. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. May 2, 2003;92(8):827-839.
121. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res. Feb 15, 2006;69(3):625-635.
122. Monaco C, Andreakos E, Kiriakidis S, et al. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and pro-thrombotic responses in human atherosclerosis. Proc Natl Acad Sci U S A. Apr 13, 2004;101(15):5634-5639.
123. Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. May 18, 1999;99(19):2503-2509.
124. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation. Apr 15, 1995;91(8):2125-2131.
125. Didangelos A, Stegemann C, Mayr M. The -omics era: Proteomics and lipidomics in vascular research. Atherosclerosis. Oct 2, 2011.
126. Halpert I, Sires UI, Roby JD, et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A. Sep 3, 1996;93(18):9748-9753.
127. Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A. Oct 25, 2005;102(43):15575-15580.
128. Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, Horton MR. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol. Jul 15, 2006;177(2):1272-1281.
129. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. Mar 30, 2001;276(13): 10229-10233.
130. Arslan F, Smeets MB, Riem Vis PW, et al. Lack of fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction. Circ Res. Mar 4, 2011;108(5): 582-592.
131. Kim S, Takahashi H, Lin WW, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. Jan 1, 2009;457(7225):102-106.
132. Babelova A, Moreth K, Tsalastra-Greul W, et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem. Sep 4, 2009;284(36):24035-24048.
133. Monaco C, Gregan SM, Navin TJ, Foxwell BM, Davies AH, Feldmann M. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation. Dec 15, 2009;120(24):2462-2469.
134. Maquart FX, Pasco S, Ramont L, Hornebeck W, Monboisse JC. An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity. Implication in tumor invasion. Crit Rev Oncol Hematol. Mar 2004;49(3):199-202.
135. Maquart FX, Bellon G, Pasco S, Monboisse JC. Matrikines in the regulation of extracellular matrix degradation. Biochimie. Mar 2005;87(3-4): 353-360.
136. Tran KT, Lamb P, Deng JS. Matrikines and matricryptins: Implications for cutaneous cancers and skin repair. J Dermatol Sci. Oct 2005; 40(1):11-20.
137. Bellon G, Martiny L, Robinet A. Matrix metalloproteinases and matrikines in angiogenesis. Crit Rev Oncol Hematol. Mar 2004;49(3):203-20.
138. Thompson MM, Jones L, Nasim A, Sayers RD, Bell PR. Angiogenesis in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. May 1996; 11(4):464-469.
139. Herron GS, Unemori E, Wong M, Rapp JH, Hibbs MH, Stoney RJ. Connective tissue proteinases and inhibitors in abdominal aortic aneurysms. Involvement of the vasa vasorum in the pathogenesis of aortic aneurysms. Arterioscler Thromb. Nov 1991;11(6):1667-1677.
140. Barascuk N, Vassiliadis E, Zheng Q, et al. Levels of Circulating MMCN-151, a Degradation Product of Mimecan, Refect Pathological Extracellular Matrix Remodeling in Apolipoprotein E Knockout Mice. Biomark Insights. 2011;6:97-106.
141. Karsdal MA, Henriksen K, Leeming DJ, Woodworth T, Vassiliadis E, Bay-Jensen AC. Novel combinations of Post-Translational Modifca-tion (PTM) neo-epitopes provide tissue-specifc biochemical markers- are they the cause or the consequence of the disease? Clin Biochem. Jul 2010;43(10-11):793-804.
142. Bauer DC, Hunter DJ, Abramson SB, et al. Classification of osteoar-thritis biomarkers: a proposed approach. Osteoarthritis Cartilage. Aug 2006;14(8):723-727.